Epidemiology of the insulin resistance syndrome

被引：82

作者：

James B. Meigs

机构：

[1] General Medicine Division, Massachusetts General Hospital, Boston, MA 02114

来源：

Current Diabetes Reports | 2003年 / 3卷 / 1期

关键词：

Metformin; Troglitazone; Metabolic Risk Factor; Diabetes Prevention Program; Insulin Resistance Syndrome;

D O I：

10.1007/s11892-003-0057-2

中图分类号：

学科分类号：

摘要：

The insulin resistance syndrome consists of the co-occurrence of metabolic risk factors for type 2 diabetes and cardiovascular disease, including over-all obesity, central obesity, dyslipidemia (characterized by elevated levels of triglycerides and low levels of high-density lipoprotein cholesterol), hyperglycemia, and hypertension. Using criteria proposed by the National Cholesterol Education Program Adult Treatment Panel III, national survey data suggest the insulin resistance syndrome is very common, affecting about 24% of US adults aged greater than 20 years. The syndrome is more common in older people and in Mexican Americans, and will increase in prevalence as populations age and become more obese. Identification of the syndrome warrants aggressive interventions known to prevent type 2 diabetes and cardiovascular disease, including weight reduction, increased physical activity, and control of hypertension and dyslipidemia. Copyright © 2003 by Current Science Inc.

引用

页码：73 / 79

页数：6

共 50 条

[1]

Boyle J.P., Honeycutt A.A., Narayan K.M., Et al., Projection of diabetes burden through 2050: Impact of changing demography and disease prevalence in the U.S, Diabetes Care, 24, pp. 1936-1940, (2001)

[2]

Mokdad A.H., Bowman B.A., Ford E.S., Et al., The continuing epidemics of obesity and diabetes in the United States, JAMA, 286, pp. 1195-1200, (2001)

[3]

Kannel W.B., McGee D.L., Diabetes and cardiovascular disease: The Framingham Study, JAMA, 241, pp. 2035-2038, (1979)

[4]

UK Prospective Diabetes Study (UKPDS) 17. A 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus, Ann. Intern. Med., 124, 1 PART 2, pp. 136-145, (1996)

[5]

Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37), Diabetes Care, 22, pp. 1125-1136, (1999)

[6]

Harris M.I., Ambulatory medical care for diabetes, Diabetes in America: Diabetes Data Compiled 1984, 25, pp. 1-13, (1985)

[7]

Economic consequences of diabetes mellitus in the U.S. in 1997, Diabetes Care, 21, pp. 296-309, (1998)

[8]

Reaven G.M., Role of insulin resistance in human disease, Diabetes, 37, pp. 1595-1607, (1988)

[9]

Meigs J.B., Invited commentary: Insulin resistance syndrome? Syndrome X? Multiple metabolic syndrome? A syndrome at all? Factor analysis reveals patterns in the fabric of correlated metabolic risk factors, Am. J. Epidemiol., 152, pp. 908-911, (2000)

[10]

Haffner S.M., Stern M.P., Hazuda H.P., Et al., Cardiovascular risk factors in confirmed prediabetic individuals: Does the clock for coronary heart disease start ticking before the onset of diabetes?, JAMA, 263, pp. 2893-2898, (1990)

← 1 2 3 4 5 →